麻豆女优

Medicare Pays For A Kidney Transplant, But Not The Drugs To Keep It Viable

Cyclosporine is one of the drugs that organ transplant patients take so the body won't reject the organ. (Brendan Gates via Flickr)

The federal government will pay more than $100,000 to give someone a kidney transplant, but after three years, the government will often stop paying for the drugs needed to keep that transplanted kidney alive.

Constance Creasey is one of the thousands of people who find themselves caught up by this peculiar feature of the .

Creasey started kidney dialysis about 12 years ago after her kidneys failed. That meant going to a dialysis center three times a week, for three hours per session. (A typical patient undergoes three to five hours of dialysis per session).

鈥淭he first three years of dialysis was hard. I walked around with this dark cloud. I didn鈥檛 want to live, I really didn鈥檛,鈥 she says.

Being dependent on these blood-cleansing machines was physically and emotionally draining. But she stuck it out for 11 years. Medicare pays for dialysis, even for people under the age of 65. It also pays for kidney transplants for people with end-stage renal disease.

鈥淔inally, a year and a half ago, transplant came. I was a little apprehensive but I said OK. And I call her Sleeping Beauty, that鈥檚 my kidney鈥檚 name.鈥

Creasey, a 60-year-old resident of Washington, D.C., no longer needs to spend her days at a dialysis center. She has enough energy for a part-time job at a home furnishing store and time to enjoy life鈥檚 simple pleasures.

鈥淚 was able to do my favorite thing 鈥 go to the pool 鈥 and I was just loving it because it鈥檚 like I had no restrictions now,鈥 she says.

But there is still a dark cloud on Creasey鈥檚 horizon. Medicare鈥檚 kidney program currently pays for a large share of the expensive drugs she needs to take twice a day to prevent her body from rejecting the transplanted kidney. But under federal rules, that coverage will disappear three years after the date of her transplant.

鈥淚 have a year and a half to prepare, or save,鈥 she says. 鈥淗ow am I going to do this?鈥

She鈥檚 already paying copays, premiums and past medical bills. She says she sleeps on the floor because she considers buying a bed a luxury she can鈥檛 afford.

She has no idea what kind of insurance she鈥檒l be able to get after her Medicare coverage runs out. And she was shocked to discover how big the bills could be. One day she went into the pharmacy to pick up her drugs, and the Medicare payment hadn鈥檛 been applied.

The pharmacist told her she鈥檇 need to pay a $600 copay for the one-month supply. 鈥淎nd I鈥檓 like are you kidding me? Six hundred? What am I going to do? I can鈥檛 pay that!鈥

A social worker at MedStar Georgetown University Hospital in Washington, D.C., where Creasey got her transplant, sorted that out. But it鈥檚 not a permanent solution.

The three-year cutoff for Medicare payments is a common problem, says , who runs the kidney transplant program at the hospital. That鈥檚 especially so since many people with serious kidney disease have low incomes in the first place.

鈥淚t鈥檚 probably about 30 percent of people who find themselves in a troublesome spot at this 36-month mark,鈥 he says.

Some people end up trying to stretch out their drug supplies by not taking them as often as they need to, he says. 鈥淲e see that a lot.鈥

But this isn鈥檛 like skipping a pain pill and bearing the consequences. People lose their transplanted kidneys through organ rejection if they don鈥檛 take their medicine religiously.

Rita Alloway, a clinical pharmacist at the University of Cincinnati, says she also encounters this false economy. 鈥淚f we were telling them to take four pills twice a day, they may start taking three pills twice a day without telling us, to extend their coverage that they had for the prescriptions they had,鈥 she says.

If people tell her that they can鈥檛 afford it, she can help them get the medications for free, Alloway says. But sometimes people are too proud to admit their financial distress, she said.

And instead of spending $15,000 a year on these anti-rejection drugs, people go back onto dialysis, which costs $90,000 a year or more. And that鈥檚 taxpayers鈥 money, provided with no time limit.

Kevin Longino, CEO of the , says it鈥檚 not just affecting the people who have transplants, but those who are on the long list waiting their turn for an organ to become available.

鈥淭he tragedy is you have so many people on the wait list already, and to have someone unnecessarily have rejection because they can鈥檛 afford the drugs and to have to go back into the system 鈥 it鈥檚 just a difficult thing to explain, why we鈥檙e allowing that to happen.鈥

Longino says insurance companies are making the problem even worse. Some have reclassified anti-rejection drugs as 鈥渟pecialty drugs,鈥 and they now require patients to pay for a percentage of the cost, rather than a more traditional fixed copayment.

Longino encountered that himself after he had a kidney transplant about a dozen years ago. He says his costs went from $150 a month to $950 a month when his insurance company made that cost-sharing shift.

He, Alloway and Cooper have been trying to persuade Congress to pass to fix this problem. Rep. Michael Burgess, R-Texas, and Rep. Ron Kind, D-Wis., have introduced bills more than once, but they have not moved through Congress. Burgess鈥 office says they plan to try again next year.

Lawmakers are concerned about the costs. Severe kidney a staggering $30 billion a year, and there鈥檚 no official cost-benefit analysis showing whether covering transplant drugs for everybody would save money overall.

鈥淭he Medicare [savings] in maintaining this drug coverage is better than putting people on dialysis,鈥 Cooper says. 鈥淭o me this is a no-brainer. I just cannot understand why we haven鈥檛 got to the point where we say Medicare coverage for life for immunosuppressive drugs because people will benefit and money will be saved.鈥

For Constance Creasey, this is not an abstract conversation.

鈥淭hose pills are my life right now,鈥 she says. 鈥淚鈥檓 trying not to worry, but it鈥檚 hard.鈥

Exit mobile version